By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

Meet the Replica Analytics Advisory Board

Anil Sethi

Anil founded 7 health-tech companies over 30 years. Has known abject failure, lead an IPO plus numerous M&A deals. Dakota exited at $40M, Sequoia IPO'd in the Spring bloodbath of 2000, then was acquired for $184M. Apple acquired Gliimpse for its Personal Health Record business where Anil was a Director of Consumer-Health Strategy and Engineering which lead in part to Apple’s push into Health Records. Devastatingly, his baby sister Tania died of hepatic complications from Stage IV metastatic breast cancer. To keep a deathbed promise to Tania, Anil founded Ciitizen to help kill cancer...in this lifetime.

a16z, Verily and Section32 invested in Sethi's most recent consumer health venture, Ciitizen, a platform that helps patients turn paper records into computable data, which are then matched to clinical trials, and more. He is a co-founder/investor in Acoustiic, a nextgen MRI & HIFU device for the ablation of brain plaque and tumour tissue using nonlethal sound for bloodless surgery (an "acoustic laser").

Anil is a partner in Andreessen Horowitz's Bio Fund III-Q, L.P., an Investment Partner in Nina Capital, the M.D. of Sethi Ventures, and a Trustee of the FBOT of the American Association of Cancer Researchers.”


Janice Branson

Janice is a strategic and influential leader with 20 years experience in Novartis Pharma AG in Basel, Switzerland and has a track record in:

  • Global Biostatistics and Data Science leadership with extensive cross-cultural experience – managing teams from India, China, Japan, US and Europe. Experienced across all therapeutic areas with more in-depth exposure to Immunology, Hepatology & Dermatology, Respiratory and Metabolism.
     
  • Analytics and Data Science leadership for Global Drug Development in the Data Science and Artificial Intelligence leadership team and on the data42 leadership team – a Novartis lighthouse project aimed at providing frictionless access to all Novartis Research and Development data.
     
  • Leading Novartis across divisions to drive forward Voluntary Data Sharing based on the EFPIA Principles for Data Sharing from a biostatistics and programming perspective and investigating anonymization methodology including bringing into Novartis the most established techniques preparing us for the future – directly applicable for implementation of EMA policy 0070.
     
  • Establishing an academic collaboration for Novartis with Oxford Big Data Institute – involved much cross discipline collaboration with data privacy, legal, IT, security and data operations as well as clinical and analytics.

Since October 2019, Janice Branson is the Global Head of Advanced Methodology and Data Science in Clinical Development & Analytics at Novartis. Prior to joining Novartis, Janice worked as a statistician at Pfizer in the UK after having completed postgraduate studies at the University of Reading U.K.


Jason Colquitt

Jason Colquitt is CEO of Across Healthcare, a company he founded in 2012.  Jason has been blessed to meet and work with many amazing people and organizations during his 20+ years in the healthcare technology field.

His work has caused a positive disruption within the healthcare industry as he has partnered with many organizations ranging from small start-ups to some of the world's largest health companies including Greenway Health, Walgreens Boots Alliance, Quintiles, IQVIA, Cystic Fibrosus Foundation, Muscular Dystrophy Association, the American College of Surgeons. 

Jason has worked directly with patients, caregivers, physicians, regulators, and researchers. Jason was diagnosed with Carnitine Palmitoyltransferase II Deficiency (CPT II), a rare mitochondrial disease, which adds a personal aspect to his passion to disrupt healthcare. Jason holds a Bachelor’s degree in Applied Mathematics from Auburn University.